Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus - PubMed (original) (raw)
. 2007 Oct;32(10):1709-17.
doi: 10.1007/s11064-007-9410-1. Epub 2007 Jun 29.
Affiliations
- PMID: 17605105
- DOI: 10.1007/s11064-007-9410-1
Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus
Ismet Tahirovic et al. Neurochem Res. 2007 Oct.
Abstract
It is believed that oxidative stress (OS) plays a central role in the pathogenesis of metabolic diseases like diabetes mellitus (DM) and its complications (like peripheral neuropathy) as well as in neurodegenerative disorders like sporadic Alzheimer's disease (sAD). Representative experimental models of these diseases are streptozotocin (STZ)-induced diabetic rats and STZ-intracerebroventricularly (STZ-icv) treated rats, in which antioxidant capacity (AC) against peroxyl (ORAC(-ROO) (*)) and hydroxyl (ORAC(-OH) (*)) free radicals (FR) was measured in three different brain regions: the hippocampus (HPC), the cerebellum (CB), and the brain stem (BS) by means of oxygen radical absorbance capacity (ORAC) assay. In the brain of both STZ-induced diabetic and STZ-icv treated rats decreased AC has been found demonstrating regionally specific distribution. In the diabetic rats these abnormalities were not associated with the development of peripheral diabetic neuropathy (PDN). Also, these abnormalities were not prevented by the intracerebroventricularly (icv) pretreatment of glucose transport inhibitor 5-thio-D: -glucose (TG) in the STZ-icv treated rats, suggesting different mechanism of STZ-induced central effects from those at the periphery. Similarities of the OS alterations in the brain of STZ-icv rats and humans with sAD could be useful in the search for the new drugs in the treatment of sAD that have antioxidant activity. In the STZ-induced diabetic animals the existence of PDN was tested by the paw pressure test, 3 weeks following the diabetes induction. Mechanical nociceptive thresholds were measured three times at 10-min intervals by applying increased pressure to the hind paw until the paw-withdrawal or overt struggling was elicited. Only those diabetic animals which demonstrated decreased withdrawal threshold values in comparison with the control non-diabetic animals (C) were considered to have developed the PDN.
Similar articles
- Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus.
Tahirovic I, Sofic E, Sapcanin A, Gavrankapetanovic I, Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z, Hoyer S, Riederer P. Tahirovic I, et al. J Neural Transm Suppl. 2007;(72):235-40. doi: 10.1007/978-3-211-73574-9_29. J Neural Transm Suppl. 2007. PMID: 17982899 - Antioxidant capacity in rat brain after intracerebroventricular treatment with streptozotocin and alloxan--a preliminary study.
Sapcanin A, Sofic E, Tahirovic I, Salkovic-Petrisic M, Hoyer S, Riederer P. Sapcanin A, et al. Neurotox Res. 2008 Apr;13(2):97-104. doi: 10.1007/BF03033561. Neurotox Res. 2008. PMID: 18515212 - Streptozotocin produces oxidative stress, inflammation and decreases BDNF concentrations to induce apoptosis of RIN5F cells and type 2 diabetes mellitus in Wistar rats.
Bathina S, Srinivas N, Das UN. Bathina S, et al. Biochem Biophys Res Commun. 2017 Apr 29;486(2):406-413. doi: 10.1016/j.bbrc.2017.03.054. Epub 2017 Mar 15. Biochem Biophys Res Commun. 2017. PMID: 28315336 - Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?
Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Correia SC, et al. Ageing Res Rev. 2011 Apr;10(2):264-73. doi: 10.1016/j.arr.2011.01.001. Epub 2011 Jan 22. Ageing Res Rev. 2011. PMID: 21262392 Free PMC article. Review. - Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
Kamat PK, Kalani A, Rai S, Tota SK, Kumar A, Ahmad AS. Kamat PK, et al. Mol Neurobiol. 2016 Sep;53(7):4548-62. doi: 10.1007/s12035-015-9384-y. Epub 2015 Aug 23. Mol Neurobiol. 2016. PMID: 26298663 Review.
Cited by
- Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.
de la Monte SM. de la Monte SM. Front Biosci (Elite Ed). 2012 Jan 1;4(4):1582-605. doi: 10.2741/e482. Front Biosci (Elite Ed). 2012. PMID: 22201977 Free PMC article. Review. - Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet.
Sodhi RK, Singh N. Sodhi RK, et al. PLoS One. 2013 Jul 31;8(7):e70487. doi: 10.1371/journal.pone.0070487. Print 2013. PLoS One. 2013. PMID: 23936214 Free PMC article. - Free radical scavenging activity and neuroprotective potentials of D138, one Cu(II)/Zn(II) Schiff-base complex derived from N,N'-bis(2-hydroxynaphthylmethylidene)-1,3-propanediamine.
Wang C, Cai ZX, You ZL, Guo HS, Shang DJ, Wang XL, Zhang L, Ma LJ, Tan J, Le WD, Li S. Wang C, et al. Neurochem Res. 2014 Sep;39(9):1834-44. doi: 10.1007/s11064-014-1392-1. Epub 2014 Jul 29. Neurochem Res. 2014. PMID: 25069642 - Tramadol ameliorates behavioural, biochemical, mitochondrial and histological alterations in ICV-STZ-induced sporadic dementia of Alzheimer's type in rats.
Dhull DK, Kumar A. Dhull DK, et al. Inflammopharmacology. 2018 Aug;26(4):925-938. doi: 10.1007/s10787-017-0431-3. Epub 2017 Dec 16. Inflammopharmacology. 2018. PMID: 29249049 - Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30.
Sofic E, Salkovic-Petrisic M, Tahirovic I, Sapcanin A, Mandel S, Youdim M, Riederer P. Sofic E, et al. J Neural Transm (Vienna). 2015 Apr;122(4):559-64. doi: 10.1007/s00702-014-1307-y. Epub 2014 Sep 25. J Neural Transm (Vienna). 2015. PMID: 25252744
References
- Clin Chem. 1995 Dec;41(12 Pt 1):1738-44 - PubMed
- Life Sci. 1990;46(1):49-54 - PubMed
- J Neural Transm (Vienna). 1998;105(4-5):415-22 - PubMed
- Endocr Rev. 2002 Oct;23(5):599-622 - PubMed
- Hum Reprod. 1999 Nov;14(11):2801-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous